Price as of close on Nov 3, 2026 · Financials updated Oct 8, 2026
Basics
Sector
Healthcare
Industry
Health Information Services
Country
United States
Market cap
1.2B USD
Enterprise value
1.4B USD
Full-time employees
697
Overall health
Strength:its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback:growing more slowly than most peersgrowing more slowly than peers
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 1.69 vs a peer median of 0.63), less short-term liquidity (current ratio 1.38 vs a peer median of 2.59) and more debt relative to equity (0.75× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.69 vs peers 0.63), less liquidity (current ratio 1.38 vs peers 2.59) and more debt vs equity (0.75× vs peers 0.22×)
About average: profitability
Ranks #836 of 1,157 healthcare companies (bottom 28%)
Stock pay is large next to buybacks. Stock-based pay expense $280M vs $479M spent repurchasing shares over the 3 fiscal years to 2025.
Over three fiscal years GoodRx recorded $280M of stock-based pay expense and spent $479M repurchasing shares (repurchases can include shares withheld to cover employees' taxes).Over three fiscal years GoodRx recorded $280M of stock-based pay expense and spent $479M repurchasing shares.
Operating margin at a 6-year high.11% in 2025, the best of the last 6 years.
GoodRx kept 11% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.
Profits growing faster than sales.Since 2022 (an unusually strong year for operating profit): revenue +4.0%, operating profit +4934%.Since 2022: revenue +4.0%, operating profit +4934%.
Since 2022, GoodRx's revenue grew 4.0% while operating profit grew 4934%: each extra dollar of sales is adding more profit.
Cash flow well above reported profit. Free cash flow is 12.2× reported profit.
Free cash flow is 12.2× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Why it changed since the Oct 27, 2026 close: Score 52 → 53
Peer companies moved+1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about GoodRx
Is GoodRx getting weaker?
Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is 39/100, up 1 since Oct 28, 2026.
How is GoodRx valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 67/100 against 1,393 healthcare peers.EBITDA yield 11.7% vs a peer median of 4.0% (stronger than 86% of peers).EBITDA yield 11.7% vs peers 4.0% (stronger than 86% of peers).
Is GoodRx growing?
More slowly than most of its peers. Growth scores 19/100 against 1,393 healthcare peers.Earnings per share growth -51.9% vs a peer median of 9.8% (weaker than 93% of peers).Earnings per share growth -51.9% vs peers 9.8% (weaker than 93% of peers).
How profitable is GoodRx?
About as profitable as its peers. Profitability scores 53/100 against 1,393 healthcare peers.
How risky is GoodRx?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 1.69 vs a peer median of 0.63 (weaker than 90% of peers).Beta 1.69 vs peers 0.63 (weaker than 90% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
787.9M USD
785.2M USD
−0.3%
Net income (12 months)
20.5M USD
16.2M USD
−21.0%
Operating margin
9.9%
9.5%
−0.4 pts
Free cash flow (12 months)
165.8M USD
197.1M USD
+18.9%
Debt
487.4M USD
486.6M USD
−0.2%
Cash
235.7M USD
296.1M USD
+25.6%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Operating margin
1.8%
0.2%
-3.6%
8.3%
11.0%
▲ 2.7 pts
Net margin
-3.4%
-4.3%
-1.2%
2.1%
3.8%
▲ 1.8 pts
Return on assets (ROA)
-1.6%
-2.0%
-0.6%
1.2%
2.2%
▲ 1.0 pts
Return on equity (ROE)
-3.0%
-4.0%
-1.2%
2.3%
4.9%
▲ 2.7 pts
Free cash flow margin
23.4%
18.6%
18.3%
23.1%
20.6%
▼ 2.4 pts
Current ratio
13.42×
12.05×
7.12×
5.32×
2.61×
▼ 51%
Debt to equity
0.81×
0.82×
0.86×
0.69×
0.80×
▲ 16%
Interest coverage
0.57×
0.05×
-0.48×
1.24×
2.05×
▲ 65%
GDRX price history
Price history is added with the daily price update and will appear after the next one.